Immune thrombocytopenia (ITP) trials in Italy
12 of 13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- Where
- Bologna, Meldola, Milan, Naples, Rome, Trieste, Turin, Vicenza
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Sanofi
See details and how to joinNCT07007962 · EU 2025-522070-36-00 - Phase 1/2Taking peopleA Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- Where
- Bologna, Milan, Rome, Trieste
- Age
- 18 years to 64 years
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06721013 · EU 2024-518502-40-00 - Phase 3Taking peopleA Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Bologna, Catania, Milan, Monza, Naples, Novara, Rome, Trieste, Turin, Vicenza
- Age
- 18 years and over
- People
- 171 worldwide
- Run by
- Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00 - Phase 1Taking peoplePhase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
- Where
- Meldola
- Age
- 18 years and over
- People
- 78 worldwide
- Run by
- Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00 - Phase 3Taking peopleA Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Bologna, Catania, Milan, Monza, Naples, Novara, Rome, Trieste, Turin, Vicenza
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00 - Phase 2Taking peopleStudy to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Where
- Bologna, Brescia, Meldola, Milan, Naples, Padova, Rome
- Age
- 18 years and over
- People
- 56 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07104565 · EU 2025-521286-27-00 - Phase 3Taking peopleA Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- Where
- Florence, Novara, Trieste, Turin, Vicenza
- Age
- 18 years to 70 years
- People
- 40 worldwide
- Run by
- Kedrion S.p.A.
See details and how to joinNCT07059000 · EU 2023-507115-35-00 - Phase 2/3Taking peopleA Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
- Where
- Florence, Genoa, Modena, Monza, Rome, Turin
- Age
- 12 years to 17 years
- People
- 24 worldwide
- Run by
- argenx
See details and how to joinNCT07194850 · EU 2025-521055-23-00 - Phase 1Taking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Meldola, Rozzano, Turin
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - Phase 1Enrolling by invitationPhase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Where
- Meldola, Milan, Torino
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06723106 - Phase 3Taking peopleA Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Where
- Bassano Del Grappa, Florence, Milan, Naples, Novara, Ravenna, Reggio Emilia, Trieste, Turin, Varese
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00 - No phaseTaking peopleBiologic Characterization of Patients With ITP
- Where
- Bologna, Piacenza, Roma, Torino, Trieste
- Age
- 18 years and over
- People
- 200
- Run by
- Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT05694325